# Vaccine Temporary Medical Exemption Clinical Criteria, Clinical Guidance and Resources

# New Zealand COVID-19 Vaccine and Immunisation Programme

Version 1.0 FINAL 6 November 2021

New Zealand Government



### **Table of Contents**

Table of Contents	2
Principles of Temporary Medical Exemption	3
Those not medical exempt	3
Medical exemption duration	3
Additional Support	7
Ministry of Health Application	8
COVID-19 Vaccine Temporary Medical Exemption	.10
Ministry of Health Approval Record	.10

#### **Principles of Temporary Medical Exemption**

- There are very few situations where a vaccine is contraindicated and, as such, a medical exemption is expected to be rarely required.
- Exemptions should be limited to situations where a suitable alternative COVID-19 vaccine is not readily available for the individual.
- Exemptions should be for a specified time, reflecting, for example, recovery from clinical conditions or the availability of alternate vaccines.
- It is likely that most people who are not medically exempt can be safely vaccinated, with some requiring extra precautions.

#### Those not medically exempt

- People who had an otherwise negative experience that is not mentioned above, with other vaccines in the past.
- Disabled people once adequate resources are available to support safe delivery. People with disabilities are generally at higher risk from COVID-19, and therefore are a priority for vaccination.
- Pregnant people. Pregnancy is not a valid reason for exemption in the absence of any of the criteria listed in the above table. Pregnancy is associated with higher risk from COVID-19 compared to the general population and therefore this group are a priority for vaccination.
- A vaccination may reasonably be deferred for individuals with some acute major medical conditions, such undergoing major surgery or hospital admission for a serious illness.

#### **Medical exemption duration**

The medical exemption duration is 6 months, with the ability to apply for a new exemption if required. This time period will allow individuals who can safely be vaccinated, with either the same vaccine or an alternative vaccine, as appropriate, to be protected against COVID-19 in a timely way.

	Criteria for Temporary COVID-19 Vaccine Medical Exemptions								
Step	Vaccine	Category	Criteria Details	Select Criteria Present	Supporting Evidence	Select Exemption Categories			
	All COVID- 19 Vaccines	1A. COVID-19 Infection	<ul> <li>PCR-confirmed SARS-CoV-2 infection until complete recovery from the acute illness.</li> <li>Note: Chronic symptoms following COVID-19 ("Long COVID") is not a contraindication to COVID-19 vaccine but does warrant a clinical discussion with the patient regarding the benefits and risks.</li> </ul>		PCR result Letter of support from their general practitioner/nurse practitioner	1A 🗆			
		1B. Serious Adverse Event to previous dose	<ul> <li>Serious adverse event attributed to a previous dose of the same COVID-19 vaccine with no other cause identified.</li> <li>An adverse event is considered serious for the purposes of these criteria if it:         <ul> <li>Requires in-patient hospitalisation or prolongation of existing hospitalisation OR results in persistent or significant disability/ incapacity.</li> <li>AND</li> <li>Has been reported to CARM.</li> </ul> </li> </ul>		CARM report Discharge summary Letter of support from the medical specialist within the relevant scope practice				

			<ul> <li>Has been determined following review by, and/or on the opinion of, a relevant medical specialist to be associated with a risk of recurrence of the serious adverse event if another dose of the same vaccine is given.</li> </ul>		<b>1B.</b> (4 of 4 criteria required)
			<ul> <li>Examples of serious AEFIs may include but are not limited to a immune thrombocytopenia purpura (ITP), myocarditis, potentia anaphylaxis), severe ME/CFS, or persistent or significant disability. These reactions do not include common expected local or system within the first few days after vaccination.</li> <li>Note: If a serious adverse event to a previous dose of a COVID the exemption, then this will require a letter of support from the first few days.</li> </ul>	ally life-threatening e ty (eg, Guillain-Barre emic reactions know -19 vaccine is used a	events (eg, é Syndrome). n to occur as a reason for
	1C. Unable to tolerate administratic due to risk to self or others		<ul> <li>Unable to tolerate vaccine administration with resulting risk to themselves or others (eg, due to severe neurodevelopmental condition such as autistic spectrum disorder).</li> <li>This may warrant a temporary exemption (maximum four weeks) while additional resources and support to facilitate a safe administration of a second dose are arranged.</li> </ul>	Letter of support from a medical specialist within the relevant scope practice	1C. 🗆
2	Pfizer Vaccine	2A. Anaphylaxis	• Anaphylaxis to the first dose of the vaccine or known severe allergy to the excipients of the vaccine as per the datasheet provided to Medsafe.	CARM report	2A. 🗆

			This criterion will be removed as an exemption when there is an alternative vaccine available in New Zealand. Many of these individuals will be able to be safely vaccinated in a controlled environment, and we recommend clinical immunologist/specialist assessment.	Discharge summary Letter of support from a medical specialist within the relevant	
		2B. Myocarditis / Pericarditis	Myocarditis/pericarditis following the first dose of the vaccine.	scope practice	2B.□
		2C. Inflammatory Cardiac Illness	Inflammatory cardiac illness within the past 6 months including: acute myocarditis, pericarditis, endocarditis, acute rheumatic fever or acute rheumatic heart disease (ie, with active myocardial inflammation).		2C.□
		2D. Acute Decompensated Heart Failure	<ul> <li>Acute decompensated heart failure.</li> <li>Although myocarditis and/or pericarditis is very rare following vaccination, if such an event were to occur, then it may exacerbate a patient's pre-existing heart failure.</li> </ul>		2D. 🗌
3	Trial Vaccine	3A. Non-Placebo participant in a vaccine trial	<ul> <li>Those who are confirmed as having the vaccine (ie, non- placebo) in any COVID-19 vaccine trial in Aotearoa New Zealand (for example, the Valneva COVID-19 vaccine trial NCT04956224).</li> </ul>	Letter of confirmation from the Vaccine Trial Clinical Lead	3A. 🗆

Other adverse events that have been reported to the Centre for Adverse Reactions Monitoring (CARM), the Immunisation Advisory Centre (IMAC), or have been observed internationally include shingles, appendicitis, lymphadenopathy with or without fever, exacerbation of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), regional pain syndrome, and neurological events with localised arm pain. These events *may or may not* be related to the vaccine and it is generally advised to defer the second dose until the symptoms have fully resolved.

#### **Additional Support**

If you or your patient are uncertain about the criteria, please consider contacting IMAC for clinical decision-making support on **0800 IMMUNE (466 863).** 



#### **Ministry of Health Application**

#### **COVID-19 Vaccine Temporary Medical Exemption**

Please send the completed application to <a href="mailto:temporarymedicalexemption@health.govt.nz">temporarymedicalexemption@health.govt.nz</a>

Consumer Details						
Full Name						
Contact Phone						
Contact Address						
Contact Email						
Address						
Vaccine Order Status	Yes 🛛 or	No 🗆	Date o	of Birth		
NHI						
Ι[		], cor	nsumer, cer	tify that	the info	ormation I
have provided to the p	ractitioner for the	purposes o	of making th	nis applic	ation is	s true.
Consumer Signature				Date Signed		
Applicant Details				·		
Full Name						
Contact Phone						
Contact Email						
Clinic Address						
Registration number						
Health Practitioner Index Number						
Category	□ 1A		□ 2A	□ 2C		□ 3A
<b>exemption criteria</b> (please tick those that apply)	□ 1B (4 of 4 criteria □ 1C	required)	□ 2B	🗆 2D		
The duration of the clin	nical relationship v	vith the con	sumer is	уе	ars	months
Ι[	] nurse prac	titioner/me	dical practi	tioner [s	elect] c	ertify that I:
Have reviewed the consumer's medical history and assessed the person's state of health. Yes / No						
Have clinical evidence se exemption criteria.	upporting the pers	son meets t	he specifie	d COVID	-19 vaco	cination Yes / No

The attached	supporting	g clinical	evidence	is:

	and the traffic constraints of the strain to the state		
I certify that I provide	e this information believing it to b	be true.	
Applicant Signature		Date	
		Signed	



## **COVID-19 Vaccine Temporary Medical Exemption**

# Ministry of Health Approval Record

Consumer Details							
Full Name							
Contact phone							
Contact email							
Contact Address							
Vaccine Order Status	Yes 🗆	or	No 🗆				
NHI							
Exemption start date							
Exemption expiry date							
Category exemption categories	□ 1A			□ 2A		2C	□ 3A
categories	□ 1B			□ 2B		2D	
	□ 1C						
Name				Role			
Signature				Date Sig	ned		



#### **COVID-19 Vaccine Temporary Medical Exemption Certificate**

PRIVATE AND CONFIDENTIAL

DATE: [insert date]

Re: VACCINE TEMPORARY MEDICAL EXEMPTION

This letter certifies that [full name of person being assessed] application has been assessed in accordance with the Ministry of Health's Temporary Medical Exemption Process and a temporary medical exemption has been granted.

This exemption is granted pursuant to clause 9B of the COVID-19 Public Health Response (Vaccinations) Order 2021.

This exemption expires after [*insert number*] months after the date of issue being [*insert date*].

This temporary medical exemption certificate is a recorded as [insert number].

[Ministry of Health]